Indeed, a number of PARP inhibitors have recently been developed for the treatment of breast tumors with homologous recombination (HR) deficiency through a synthetic lethality mechanism, especially those with mutations in the breast cancer susceptibility genes BRCA1 and BRCA2, which encode proteins critical for DNA repair by HR [16–19]. The gene discussed is PARP1; the disease is breast cancer.